Microsoft word - 100121 research wall chart.doc

Research
Coordinator
Alternate Name
Pharmacy Supplies
Description
A multicenter, single arm, non-blinded safety and dose
TMC-CLV-07-
Rebecca Violette: 662-2066,
Accelerate
Clevidipine in 100ml Type II clear glass
titration study evaluating the ability of clevidipine to rapidly
Clevidipine
pager: 741-3257, fax: 662-
control elevated blood pressure in the setting of and acute
intracerebral hemorrhage (ICH)
6326.The Medicines Company
Acyclovir in Neonatal
Carol McCarthy, MD 662-
Zovirax™
Two studies using acyclovir to suppress herpes after
Acyclovir
Acyclovir or placebo
5522; Pager 767-6781
Herpes Suppression
treatment for CNS infections or skin-eye-mouth infection
Biologic lung volume reduction by obstructing selected upper
AERIS 01-C07-001
207-662-4519
Hydrogel
Hydrogel for bronchoscopy
lobe areas with hydrogel. Done under bronchoscopy for
AERIS Therapeutics
emphysema, etc
Boceprevir & PEG2b/Ribavirin for the treatment of Chronic
Erythropoietin,
Anemia P06086
Erythropoietin, Ribavirin,
Hepatitis C in Treatment-Naïve Subjects:A Comparison of
Sue Mortenson,396-8078, fax
Ribavirin,
PEG2b,Boceprevir
Erythropoietin Use VS. Ribavirin Dose Reduction for the
885-8391, pager 741-0597
PEG2b,Boceprevir
Management of Anemia.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi- GS-US-300-
Center, Parallel-Group Study to Evaluate the Efficacy and Safety ARTEMIS-PH
Ambrisentan,
662-4519, fax 761-3022,
Ambrisentan/Placebo
of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis Letairis
pager 741-7234
Determine if the initial adjunctive use of Pharmacomechanical
Activase
Catheter-Directed Thrombolysis (PCDT) in symptomatic
Renee Daigle, MA phone 883-
(Recombinant Tissue
Activase
patients with acute proximal deep vein thrombosis reduces the 5295, pager N/A
Plasminogen
occurrence of the Post-Thrombotic Syndrome over 24 months NIH
Activator, rt-PA)
follow-up.
Randomized, Placebo-Controlled Comparison of the Effects of
AWARD H9X-MC-GBDA
LY2189265 and
LY2189265, Exenatide, Metformin, and
Two Doses of LY2189265 or Exenatide on Glycemic Control in Judy DeMena, 396-8062, fax
Exenatide
pioglitatonze
Patients with Type 2 Diabetes on Stable Doses of Metformin 885-8391
and Pioglitazone
Joanne Burgess 0678 767-
Vascular endothelial growth factor is placed in an adenovirus
AWARE Cardium®
Drug to cath lab. Stored in ultra cold
and injected through cardiac cath to promote collateral
Cardium Therapeutics
circulation in coronary artery disease
Cyclosporin oral vs 2 regimens of
Krista Garrison Office 7191
Belatacept
Belatacept injections during transplant
Belatacept vs Cyclosporin for immunosuppression in renal
Page 741-1409
and as outpatient every 4 weeks x 1
transplant
(BRISTOL-MYERS SQUIBB)
Robin Donovan 883-0069
Bevacizumab GOG
Bevacizumab every 3 weeks x 5 cycles
Bevacizumab, an antiangiogenesis drug in combination with
Fax 8837972 (NCI-
Avastin™
or x22 cycles vs placebo
conventional therapy for late stage ovarian cancer
GYNECOLOGIC ONCOLOGY
GROUP)

A Randomized, Double-blind, Parallel-group Study to
Assess the Safety and Efficacy of Asacol (1.2 to 4.8g/day)
Asacol®
Mesalamine/placebo tablets in numbered
Tim Messitt, phone: 662-
Mesalamine
400mg Delayed-released Tablets Given Twice Daily for 26
Weeks to Children and Adolescents for the Maintenance of 6712, fax: 662-5528
Remission of Ulcerative Colitis.
A Randomized, Multi-Center, Double-Blind, Parallel,
28431754
Judy DeMena, 396-8062, fax
Canagliflozin
Canagliflozin
Placebo-Controlled Study of The Effects of JNJ-28431754
(Canagliflozin)
on Cardiovascular Outcomes in Adult Subjects With Type 2 885-8391
Diabetes Mellitus
CCS Mike Butts775-3600
Me Childrens Cancer Pgm
COG P9962
NSC 609699
Intrathecal injection
Phase II trial in patients with refractory meningeal
Topotecan
Kathleen Glick 8857565
(Critical Care Systems)
malignancies
(CHILDRENS ONCOLOGY
GROUP)
CCS Mike Butts775-3600

Me Childrens Cancer PGM
Injection
Irinotecan
Phase II trial for refractory solid tumors
Kathleen Glick 8857565
(Critical Care Systems)
(CHILDRENS ONCOLOGY
GROUP)

B-Cell depletion by anti-CD20 (Rituximab) in renal allograft
CTOT-02 Rituximab
recipients who develop de novo anti-HLA alloantibodies will
Krista Garrison 662-7191, fax
Rituximab
Rituximab vials
result in inhibition of alloantibody production and attenuation 662-7160, pager 741-1409
of chronic humoral rejection (CTOT-02)
A Phase II single arm study of carboplatin and Doxil plus
DOXIL DOXILOVC2007
Carboplatin,Doxil,
Patricia Shorthill 662-5719,
Stored and dispensed at Scarborough
bevacizumab in subjects with platinum sensitive recurrent
Bevacizumab
pager 741-0308
ovarian, fallopian tube and primary peritoneal cancers
Protocol
desvenlafaxine
Titration Kits, Treatment bottles, and
A double-blind, placebo-controlled study assessing the safety Judy DeMena,phone662-
3151A2-3353-
cuccinate sustained
Taper packages of DVS-SR. All stored
and efficacy of DVS-SR for the treatment of vasomotor
8310,pager 741-1993
release tablets or
in vault.
symptoms associated with menopause.
CCS Mike Butts775-3600
Erwinase™ Erwinia L
Subcutaneous injection supplied from
Me Childrens Cancer Pgm
For pediatric ALL patients allergic to E Coli Asparaginase
Asparaginase
Critical Care Systems
Kathleen Glick 8857565
(Fisher Bioservices)

Alteplase
To determine the optimal strategy in the prevention and
Jane Kane,RN, phone:662-
(Braxton,
Alteplase (limited supply to be stored in elimination of intraluminal saphenous vein graft clot in patients
Activase®, alteplase
6991,fax: 662-2894, pager:
undergoing Endoscopic saphenous vein harvesting for coronary
Kramer,MD)
741-6453
artery bypass grafting.
A 16-Week, International, Multi-center, Double-Blind, TDE-PH-308
Treprostinil
Randomized, Placebo-Controlled Study of the Efficacy and Treprostinil diethanolamine/
662-4519, pager: 741-7234,
diethanolamine/
Safety of Oral UT-15C Sustained Release Tablets in Subjects Remodulinn
Placeboo
fax: 741-30222
Placeboo
PEG,PVP, Na
Gelclair® is a proprietary oral protectant that adheres to and
Hyapuronate,
protects mucosal surfaces damaged by radiation for head and
Kits with active drug or sodium
Donna Green and Cyndi O'Brien
Bioadherent
Hydroxyehtyl-
neck cancer. Patients are randomized to Gelclair™ or
Gelclair®
cellulose,
bicarbonate standard treatment
[email protected], 6776
standard therapy which is sodium bicarbonate rinse.
Glycyrrhetinic
together with supplies such as
fax:6770
Evaluating staff are blinded as kits are shipped directly from
acid, vs.
toothbrush, mouthwash, etc
pharmacy to patient’s home and patient5 is contacted by a
separate unblended third party.
GOG-0129Q Gemcitabine
A Phase II evaluation of Gemcitabine in the treatment of recurrent or persistant endometrial carcinoma. Mifeprostone is a progestin receptor antagonist which inhibits
Oral tablets are stored and dispensed
Mifepristone
growth of ovarian epithelial cells. Patients will receive 200mg
by the research nurse in the Gynecologic
Robin Donovan 883-0069
orally daily to estimate anti-tumor response in persistent or
oncology practice off site in
Fax 8837972 (NCI-GOG)
Mifeprex™
recurrent epithelial ovarian, fallopian or primary peritoneal
Scarborough
carcinoma. Original use is as an abortifacent
Doxorubicin
Doxorubicin-Cisplatin-Paclitaxel vs
Compare the two regimens in Stage III & IV recurrent
Robin Donovan 883-0069
Cisplatin Paclitaxel
Carboplatin-Paclitaxel every 21 days
endometrial cancer to determine if the two drug is as
Fax 8837972 (NCI-GOG)
Carboplatin
times 7 cycles
effective and less toxic than the 3 drug regimen
Robin Donovan 883-0069
Bevacizumab
Bevacizumab every 3 weeks x 5 cycles
Bevacizumab, an antiangiogenesis drug in combination with
Avastin™
Fax 8837972 (NCI-GOG)
or x22 cycles vs. placebo
conventional therapy for late stage ovarian cancer
In cervical carcinoma limited to the pelvis, tirapazamine will
Tirapazamine injection along with
be given with cisplatin along with radiotherapy. Tirapazamine Robin Donovan 883-0069
Tirapazamine
cisplatin to outpatients in the
is a hypoxia selective anti-tumor agent thought to enhance
Fax 8837972 (NCI-GOG)
Scarborough infusion room
cisplatin anti-tumor efficacy
A PHASE II EVALUATION OF PACLITAXEL, CARBOPLATIN,
AND BSI-201 IN THE TREATMENT OF ADVANCED,
BIPAR#20070102
PERSISTENT, OR RECURRENT UTERINE CACINOSARCOMA Fax 8837972
AZD6244 is supplied as 50 or 100mg
A Phase II Trial of AZD6244 (NSC #741078, IND #77782)
powder vials in boxes containing 16 vials.
In Women With Recurrent Low-Grade Serous Carcinoma Of
Captisol is supplied in boxes containing
The Ovary.
16 blow fill seals(BFS)/box.
A Prospective, multi-center, randomized, double-blind trial to
assess the effectiveness and safety of 12 versus 30 months
of dual Anti-platelet therapy (DAPT) in subjects undergoing
HCRI-DAPT DAPT,
Clopidogrel, Prasugrel, Placebo
Percutaneous coronary intervention (PCI) with either drug-
Jeannie Gallant, 662-3408, fax 662-6315 eluting stent (DES) or bare metal stent (BMS) placement for
the treatment of coronary artery lesions.
A Phase 3, Randomized, Double-Blind, Cross-Over, Active-
Buphenyl (sodium phenylbutyrate,
Controlled Study of the Efficacy and Safety of HPN-100,
Sue Mortensen, phone: (207)
HPN-100-006 phenylbutyric acid.
NaPBA,4-phenylbutyric acid, HPN-100,
Glyceryl tri-(4-phenylbutrate), for the Treatment of Adults 396-8078, fax: 885-8391, pager
with Urea Cycle Disorders
741-0597
To determine the safety and tolerability of inhaled hypertonic In-House study:
Hyper-Saline Hyper-Sal
7% Hypertonic Saline
From Vault, vials of 7% hypertonic
saline (HTS) in patients with cystic fibrosis CF) and forced
Dr. Zuckerman and Dr. Mahesh
expiratory volume in one second (FEV1)less than 40% of
predicted.
A Multicenter, Randomized. Double-Blind, Double-Dummy, Judy DeMena,phone 662-
Lutrepatch/Placebo
Lutrepatch/Placebo kits, bottles of 5
Placebo-Controlled Study to Assess the Efficacy and Safety of Three LUTREPATCH GnRH
8310,pager 741-1993
tablets of Medroxyprogesterone. All
Dosage Strengths of Pulsatile GnRH Delivered from an Medroxyprogesterone
meds are in vault.
Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment with Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory Safety & efficacy of long term mannitol inhalation in cystic
Rhoda Kennedy-DuDevoir 207-
MANNITOL DPM-CF-302
Outpatient prescriptions of mannitol for
fibrosis. Inhalation may improve mucociliary clearance as an
662-6550 Pager 741-7234
Mannitol inhalation
inhalation
osmotic agent increasing hydration or change viscoelastic
Fax 207-761-3022
properties of mucous
PHARMAXIS
Capsules prepared by pharmacy with
MISOPROSTIL
Elizabeth Linell 662-6219 fax
Misoprostil
active misoprostil or placebo supplied in
Use to dilate neck of cervix before endometrial biopsy.
662-2702 MMC OB/Gyn clinic
kits to OB-Gyn clinic
Early access study in patients who have failed on other
Raltagravir™
Oral tablets to outpatients along with
regimens. MK-0518 is an antiretroviral HIV-1 integrase
Sandra Putnam 2995 page
L-000900612
inhibitor. It inhibits the insertion of HIV-1 DNA into host
7676655 MERCK
A study to do a prospective, randomized trial to determine
whether prophylactic ascorbic acid alone, ascorbic acid with
How to drive
Jane Kane, RN, phone:662-
Ascorbic Acid 500mg chewable tablets
amiodarone, or amiodarone alone, when given along with beta
Ascorbic Acid
6991, fax: 662-2894, pager:
Clay nuts!
and amiodarone 200mg oral tablets
blockers will decrease the incidence of postoperative AF in
741-6453
adult cardiac surgery in all comers as compared with beta
blockers alone.
Claire Berg, Joanne Burgess,
A prospective, randomized, multicenter trial to assess an
and fJeannie Gallant
Platinum S2046
Plavix, clopidogrel
Plavix, #180 or Ticlid #360
Everolimus-Eluting stent system for the treatment of up to
phone:662-4897, pager:767-
and Ticlid, ticlopidine
two De Novo coronary artery lesions.
6785
Boston Scientific Corporation

Planned Transition to Sirolimus-based Therapy versus Tacrolimus Krista Garrison phone: 662-
Planned Transition
0468E8-4500
Rapamune, Sirolimus
Rapamune, Sirolimus
7191, fax: 662-7160, pager:
741-1409
A phase 1-2, multi-center, dose escalation study of a single Krista Garrison phone: 662-
Proteon PRT-201-101
dose of PRT-201 administered immediately after
PRT-201/pl;acebo
7191, pager 741-1409
Arteriovenous fistula creation in patients with chronic kidney Proteon Therapeutics
disease.
Tracy Robbins& Laurel Libby
Quetiapine Seroquel™
50mg tablets and matching placebo to
Safety and efficacy of Quetiapine in treatment of ICU
2066 741-3257
quetiapine
inpatients in varying doses every 12 hrs
delirium

(INTERNAL)

Ramipril has an unexplained protective effect on kidneys
independent of blood pressure lowering. This study tests the
RAPAMUNE
Krista Garrison Office 7191
Prescriptions dispensed from MMC
efficacy of Ramipril in preventing a urinary protein to
Ramipril and sirolimus
Page 741-1409
0468E5-4439
pharmacy
creatinine ratio (U p/c) greater than 0.5 following conversion WYETH
to sirolimus from a calcineurin inhibitor (CNI) in maintenance
kidney transplant patients
Open label extension study of the long term safety of
Rhoda Kennedy-Dudevoir 662-
RECAP PIPF-012
Rx through Out Patient pharmacy.
Pirfenidone, Placebo
Pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) 6550,page 741-7234.Tina
Bottles of #180
who complete the CAPACITY Study.
Manly 662-4519
Jane Kane, RN, phone:662-

RED-CABG Acadesine
Acadesine diluted in IV bag, cardioplegia
Reduction in Cardiovascular Events By AcaDesine in
Acadesine
6991, fax: 662-2894, pager:
solution
Patients Undergoing CABG
741-6453
ACT-064992,
Seraphin (ACT-064992) 3mg, 10mg, or To demonstrate that either dose of ACT-064992 prolongs the Tina Manley & Rhoda Kennedy-
SERAPHIN
Seraphin
placebo, in kits of 6 bottles, 36
time to the first morbidity or mortality event in patients with DuDevoir,phone 662-4519
AC-055-302
tabs/bottle
symptomatic pulmonary arterial hypertension.
Actelion
A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-
BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE
Patricia Shorthill, phone 883-
SHH4489g GDC-0449
GDC-0449 or
From vault, GDC-0449/Placebo
EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE
0069, pager 741-0308
placebo (150mg)
THERAPY IN PATIENTS WITH OVARIAN CANCER IN A
Genentech
SECOND OR THIRD COMPLETE REMISSION
Study the efficacy and safety of Sorafenib compared to
BAY 43-9006
Sorafenib/Placebo bottles, #140,
Patricia Shorthill 741-0308
SORAFENIB
Sorafenib
placebo in ovarian epithelial cancer or primary peritoneal
200mg. Dispensed through Out-Patient
Nexavar®
(Nexavar®),Placebo
cancer patients who have achieved a complete clinical response
Pharmacy
after standard platinum/taxane chemotherapy.
B1321001
A phase 3, multi center, double-blind, placebo-controlled,
Tina Manley phone: 662-4519,
B1321002
Blister pack (32 day supply) of
Thelin, Sitaxsentan
safety and efficacy study of sitaxsentan sodium in subjects
pager: 741-7234
sitaxsentan 100mg or placebo
B1321003
with pulmonary arterial hypertension.
BHR-100 (6% IV fat
A Randomized, Double-Blind, Placebo Controlled Phase III
Steven Desjardins 774-2381,
Synapse BHR-100-301
emulsion containing
BHR-100/Placebo
Study to Investigate the Efficacy and Safety of Progesterone fax 774-0459, pager 741-
2.0mg/ml
in Patients with Severe Traumatic Brain Injury
progesterone
Tim Messitt Maine Pediatric
Studied in cystic fibrosis patients. PGY2 receptor agonist that Specialty Group 887
TIGER-2 Denufosol
Outpatient prescriptions of inhalation
causes chloride and liquid secretion in the airway and
Congress St., Ste 320 Portland,
Tetrasodium
solution
stimulates mucous production and ciliary action to restore or ME 04102
maintain mucociliary clearance
Ph: 662.6712 Fax: 662.5527
[email protected]
Tim Messitt Maine Pediatric
Specialty Group 887

TIGER-OLE Denufosol
Outpatient prescriptions of inhalation
For patients who have completed TIGER-2 protocol. Study
Congress St., Ste 320 Portland,
Tetrasodium
solution
provides patients with an additional 48 weeks of medication . ME 04102
Ph: 662.6712 Fax: 662.5527
[email protected]

A Phase 3, Open-Label Study of the Safety of HPN-100 for Sue Mortensen, phone: (207)
TREAT-UCD HPN-100 HPN-100
the Long Term Treatment of
396-8078, fax: 885-8391,
Urea Cycle Disorders
pager 741-0597
Only available as investigational drug under “Expanded
Physician requesting becomes
VARIZIG VZIG
Varicella Zoster
Immune globulin for Varicella zoster
Access Protocol” May be available for pediatric patients at
principal investigator
Immune Globulin
exposure in immunocompromised patients
Critical Care Systems. For adults will have to obtain from
(CANGENE)
sponsor under a tight timeline.
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-
Tim Messitt Maine Pediatric
VX-770/Placebo, 150mg oral blue film-
CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE Specialty Group 887
VERTEX VX-770
coated tablets. Supplied in kits of 4
SAFETY AND EFFICACY OF VX-770 IN SUBJECTS AGED 12 Congress St., Ste 320 Portland,
weekly child-resistant blister dosing
YEARS AND OLDER WITH CYSTIC FIBROSIS WHO ARE
HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION.
Ph: 662.6712 Fax: 662.5527
[email protected]
Voraxaze is ordered on a patient
An Open Label Treatment Protocol For The Use Of Voraxaze
VORAXAZE
Kathleen Glick, phone: 885-
Voraxaze
specific need: it is not stocked. The
As Adjunctive Treatment For Patients Experiencing Or At Risk
7565, fax: 885-7577
$10,000 vials are refrigerated.
Of Methotrexate Toxicity
A Prospective, multi-center, randomized, double-blind trial to
assess the effectiveness and safety of 12 versus 30 months
of dual Antiplatelet therapy (DAPT) in subjects undergoing
Numbered kits containing either:
Jeannie Gallant, phone: 662-
Clopidogrel, prasugrel
clopidogrel, prasugrel, or placebo.
Percutaneous coronary intervention (PCI) with either drug-
3408, fax: 662-6315
eluting stent (DES) or bare metal stent (BMS) placement for
the treatment of coronary artery lesions.

Source: http://www.mmcri.org/deptPages/resss/downloads/ResearchDrugSummary.pdf

Fact sheet lev desitin d

Anwendung LEV DESITIN® kann mahlzeitenunabhängigen mit oder ohne Nahrung eingenommen werden. Bei der empfohlenen Einnahme werden die LEV DESITIN®-Minitabletten direkt aus dem Beutel in den Mund eingenommen. Anschließend sollte mit ausreichend Flüssigkeit (z. B. einem Glas Wasser oder Fruchtsaft) Kompendium LEV DESITIN® Einnahmeempfehlung (Levetiracetam) 1.

08-0048 1.7

Published Online First on April 14, 2008 as 10.1158/1940-6207.CAPR-08-0048 Impact of Economic, Regulatory, and Patent Policies on Innovationin Cancer ChemopreventionChemoprevention agents are an emerging new scientific area that holds out thepromise of delaying or avoiding a number of common cancers. These new agents facesignificant scientific, regulatory, and economic barriers, however, whic

Copyright © 2010-2014 Drug Shortages pdf